Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
| العنوان: | Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study |
|---|---|
| المؤلفون: | Hesham Mohamed, Teresa Zyczynski, Yuanxin Rong, Elisabetta Abruzzese, Loretta A. Williams, Susanne Saussele, Dong-Wook Kim, Javier Pinilla-Ibarz |
| المصدر: | Annals of Hematology |
| بيانات النشر: | Springer Science and Business Media LLC, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Male, Quality of life, medicine.medical_specialty, Dasatinib, Young Adult, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, Humans, Medicine, Patient Reported Outcome Measures, Adverse effect, Protein Kinase Inhibitors, Tyrosine kinase, Aged, Aged, 80 and over, Hematology, Drug Substitution, Adverse effects, business.industry, Chronic myeloid leukemia, Myeloid leukemia, Imatinib, General Medicine, Middle Aged, Rash, Treatment Outcome, Imatinib mesylate, Tolerability, 030220 oncology & carcinogenesis, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, Original Article, medicine.symptom, business, 030215 immunology, medicine.drug |
| الوصف: | Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib. These events may decrease patient quality of life and adherence, and may ultimately contribute to a suboptimal response. Alternative, second-generation tyrosine kinase inhibitors, such as dasatinib, are available with the potential to reduce adverse events, improve tolerability, and support long-term treatment goals. We present the final, primary analysis of DASPERSE/CA180-400 (NCT01660906), an open-label, multicenter, phase IV study designed to determine whether chronic, low-grade nonhematologic adverse events in imatinib-treated patients improve after switching to dasatinib, without affecting efficacy. Of the 121 chronic, grade 1/2, imatinib-related adverse events identified at baseline in 39 patients, 77% resolved or improved within 3 months after switching to dasatinib. Dasatinib maintained a consistent safety profile; headache (33%), pleural effusion (26%), fatigue (23%), and rash (23%) were the most common treatment-related adverse events after the switch. Patients either maintained (56%) or improved (44%) their molecular response on dasatinib. Patients who switched to dasatinib also experienced improved patient-reported symptom burden from baseline as assessed by the MD Anderson Symptom Inventory for chronic myeloid leukemia (on a 1–10 scale, mean change in disease-specific score was − 2.24 and core symptom severity score was − 1.06). Overall, the efficacy and quality of life/symptom burden improved in many patients, despite the onset of dasatinib-related adverse events in most patients. This suggests that imatinib-treated patients with chronic, low-grade adverse events could benefit from switching to treatment with dasatinib. Electronic supplementary material The online version of this article (10.1007/s00277-018-3295-8) contains supplementary material, which is available to authorized users. |
| تدمد: | 1432-0584 0939-5555 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a1a5c57c107e4e95e9f677715daf18 https://doi.org/10.1007/s00277-018-3295-8 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....a7a1a5c57c107e4e95e9f677715daf18 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14320584 09395555 |
|---|